June 9, 2020 08:22 AM EDTUpdated 03:44 PM
Cell/Gene Tx

Sanofi sends a pair of gene ther­a­pies back to Ox­ford Bio­med­ica. Are they sal­vage­able?

Jason Mast

Editor

The same day Ox­ford Bio­med­ica signed a 5-year deal to make As­traZeneca’s Covid-19 vac­cine, the UK gene ther­a­py com­pa­ny an­nounced they re­ceived word Sanofi …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

Roche teams with Flare Ther­a­peu­tics on tran­scrip­tion fac­tors

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times